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http://dx.doi.org/10.1016/j.pedneo.2Long QT syndrome is a congenital disorder accompanied by a high incidence of sudden cardiac
death. b-adrenergic blockade is the therapy of choice, and it is successful in 75e80% of
patients. However, for those in whom refractory arrhythmia or cardiac events are not pre-
vented by medication, the literature suggests that left cardiac sympathetic denervation may
be useful. Here we present a girl 20 months of age with refractory ventricular tachycardia
due to long QT syndrome successfully treated by left cardiac sympathetic denervation. There
was no significant complication.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Long QT syndrome is a disorder of myocardial repolarization
characterized by a prolonged corrected QT interval (QTc)ediatric Cardiology, Depart-
ans General Hospital, 160,
40705, Taiwan, ROC.
.com (Y.-C. Fu).
an Pediatric Association. Publish
012.08.014on electrocardiography (ECG) and ventricular arrhythmias,
usually torsades de pointes, which may result in sudden
death. Patients with long QT syndrome may present with
complaints of syncope, seizures, or palpitation during
exercise or with emotion.1 The first manifestation may be
cardiac arrest.2,3 The prevalence of long QT syndrome is
estimated to be 1 in 5000 to 7000 people of the general
population. The mortality of untreated symptomatic
patients is up to 70%.4,5 b-adrenergic blockade is
the therapy of first choice.3,4 However, approximatelyed by Elsevier Taiwan LLC. All rights reserved.
Sympathectomy for long QT syndrome 379a quarter of patients with full doses still have syncope
attack and are in danger of sudden cardiac death.4,6 The
other forms of therapy include mutant channel targeted
therapies such as mexiletine, permanent pacemakers, and
implantable cardioverter defibrillators (ICDs).2 The latter
are often inapplicable in children due to potential compli-
cations such as lead dislodgement and inappropriate size.
Research has suggested left cardiac sympathetic denerva-
tion (LCSD) as an alternative effective therapy for those
who have failed with or have intolerance to b-adrenergic
blockade.5,7,8 Here we report on a girl 20 months of age
with long QT syndrome who has refractory ventricular
arrhythmia that was successfully treated by LCSD.
2. Case Report
A female patient aged 14 years presented with sudden
cardiac arrest at the age of 6 months during sleep. After
resuscitation, she developed hypoxic encephalopathy. An
irregular heartbeat was noted at the age of 10 months.
Twelve-lead ECG showed a prolonged QTc of 444-472 msec
(Figure 1) with frequent episodes of nonsustained torsades
de pointes ventricular tachycardia (VT; Figure 2). Echo-
cardiography showed no structural abnormality. She had no
deafness, but her mother and elder brother had prolonged
QTc (460 and 470 milliseconds, respectively) without
symptoms. She had no mutation in KvLQT1, SCN5A, or
KCNE1 genes, but single nucleotide polymorphisms were
reported, including H558R in SCN5A, and G38S in KCNE1,
respectively. She received oral propranolol 3 mg/kg/day
and mexiletine 10 mg/kg/day but the nonsustained
torsades de pointes VT persisted. At the age of 19 months,
she was admitted to our intensive care unit due to poor
perfusion caused by repeated and exacerbated arrhythmic
episodes. She presented with a pale appearance and irri-
table crying, and there were no concomitant febrile events
or significant electrolyte abnormalities. Echocardiography
showed left ventricular dilatation and hypokinesia with
ejection fraction of 57%. Combined therapy with oral
propranolol 4 mg/kg/day, mexiletine 15 mg/kg/day,
phenytoin 5 mg/kg/day, and intravenous lidocaine 50 mg/
kg/minute was administered but the VT was still poorly
controlled. After discussion with the patient’s parents and
informed consent was obtained, left high sympathetic
denervation involving the lower part of the stellate
ganglion and the first four thoracic ganglia was performed
at the age of 20 months. After operation, the arrhythmia
was well controlled and lidocaine and phenytoin were dis-
continued gradually in 5 days. No Horner syndrome or other
complications were found except for diminished sweating
of left upper limb. The QTc decreased to 427e457 milli-
seconds (Figure 3). ECG monitoring showed that the
episode and duration of torsades de pointes VT was signif-
icantly decreased. The patient was discharged with the
medication of oral propranolol 4 mg/kg/day and mexiletine
10 mg/kg/day. ECG at the age of 28 months showed no
polymorphic ventricular tachyarrhythmia induced by
isoproterenol infusion test. During 12 years of follow-up,
she only experienced two episodes of VT induced by
infection-related febrile events that demanded hospitali-
zation. Otherwise, the patient was asymptomatic and well.3. Discussion
Ion channels that control the electrical activity of the
myocardium are defective in long QT syndrome. It is often
caused by mutation of more than 12 genes of these ion
channels. In addition to a catalogue of mutations of these
genes, a number of sequence variant polymorphisms have
also been reported in these genes. These variants have
been associated with repolarization, cardiac conduction
defects, and altered QT interval and have been proposed as
disease-modifying factors, which may play a role in family
genetic counseling. The polymorphism H558R in SCN5A had
been shown to modulate the biophysical effect of an SCN5A
mutation; however, polymorphism G38S in KCNE1 showed
an uncertain effect on QT interval.9 Although a different
treatment plan could be used according to these mutations
and polymorphisms, this is clinically limited because of the
poor availability of genetic diagnosis and difficulty in
interpretation.
The standard prevention treatment is b-adrenergic
blockade, which prevents syncope and sudden cardiac
death.2e4 For those who cannot tolerate or fail with
b-adrenergic blockade therapy, treatment targeted to
mutant channel could be considered. Sodium channel
blocker such as mexiletine has been proved to be effective
in some clinical settings.2,10 For those with aborted cardiac
arrests or recurrent cardiac events despite conventional
therapy, ICD was indicated.11 Although ICD can prevent
sudden death, excessive shock due to repeated arrhythmic
episodes is a problem. ICD may introduce side effects as
inappropriate shocks, infections or lead dislodgement.3,7
Since LCSD was first held by Moss8 in 1969, it has
provided an alternative therapy for patients refractory to
pharmacology. The mechanism of LCSD arises from
suppression of sympathetic innervation to the left
ventricle, which contributes to shortening of prolonged QT
interval, reduction in QT dispersion and thereby to
decreasing the probability of malignant arrhythmia.5,6 The
animal and human model shows that the sympathetic
activation associated with syncopal episodes.12 Recent
studies confirmed the highly specific arrhythmogenic
potential of left-sided cardiac sympathetic nerves13; that
is, by lowering sympathetic potential, the LCSD reduces the
risk of cardiac arrest episodes. Therefore, LCSD not only
interferes with the “trigger,” represented by sympathetic
activation, but also changes the arrhythmogenic substrate,
represented by reduced QT interval.7
Two large series of experience of LCSD were reported in
1991 and 2004.5,7 Schwartz et al in 2004 reported 147
patients of long QT syndrome who underwent LCSD.7 They
reported that the mean annual cardiac event per rate per
patient dropped by 91%. The percentage of patients with
more than five cardiac events declined from 55% to 8%. In
patients with preoperative ICD and multiple discharges, the
post-LCSD count of shocks decreased by 95% from a median
number of 25 to zero per patient.7 The newer approach of
LCSD with video-assisted thoracoscopy achieves better
outcomes and lower complication rates, making it the first-
line therapy for long QT syndrome.12,14,15
Fatal arrhythmic events are significantly reduced by
LCSD, but they cannot be entirely prevented.7 In our case,
Figure 1 Pre-LCSD ECG shows prolonged QTc of 444e472 milliseconds. ECGZ electrocardiography; LCSDZ left cardiac
sympathetic denervation; QTc Z corrected QT interval.
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Figure 2 ECG shows torsades de pointes VT. ECGZ electrocardiography; VTZ ventricular tachycardia.
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Figure 3 ECG taken 2 years after LCSD shows normal sinus rhythm with a QTc of 431 milliseconds. ECGZ electrocardiography;
LCSDZ left cardiac sympathetic denervation; QTc Z corrected QT interval.
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Sympathectomy for long QT syndrome 383there were still several VT episodes after LCSD, which may
suggest LCSD alone to be inadequate. Therefore the risk-to-
benefit ratio of ICD when older should be carefully
weighed.
In conclusion, from our limited experience and the
literature, LCSD is a safe and beneficial method to control
refractory ventricular arrhythmia in patients with long QT
syndrome, especially in young children when ICD is not
applicable. However, LCSD may not completely control the
arrhythmic events. Thus, the choice of ICD or LCSD use
should be determined on an individual basis.
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